Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Periprocedural heparin or aspirin during endovascular treatment for acute ischemic stroke
ISRCTN76741621Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin and heparin in ischemic stroke (4 arms), sponsored by Erasmus MC. Primary endpoint: Functional outcome at 90 days. Started Nov 2017; status: completed.
02
Drugs
aspirinheparin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ISRCTN76741621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN76741621.